scispace - formally typeset
B

Brenda J. Sickle-Santanello

Researcher at Ohio State University

Publications -  14
Citations -  560

Brenda J. Sickle-Santanello is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Carcinoembryonic antigen. The author has an hindex of 11, co-authored 13 publications receiving 553 citations. Previous affiliations of Brenda J. Sickle-Santanello include University of Cincinnati.

Papers
More filters
Journal ArticleDOI

Radioimmunoguided surgery using monoclonal antibody.

TL;DR: Improved selection of patients for antigen-positive tumors, the use of higher affinity second-generation antibodies, alternate routes of antibody administration, alternate radionuclides, and more sophisticatedly bioengineered antibodies and antibody combinations should all lead to improvements in radioimmunoguided surgery.
Journal ArticleDOI

Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors

TL;DR: The authors have developed a hand-held gamma-detecting probe (GDP) for intraoperative use that improves the sensitivity of external radioimmunodetection and may influence the short-term morbidity and mortality of surgery for colorectal cancer.
Journal ArticleDOI

Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal

TL;DR: Treatment of patients with combined chemotherapy and radiation therapy for anal cancer and abdominoperineal resection confirmed a high complete response rate, and local treatment failures may occur, but these may be salvaged with abdomen resection.
Journal ArticleDOI

Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma?

TL;DR: It is concluded that simple determination of DNA ploidy fails to indicate prognosis for infiltrative, node‐negative breast carcinoma and the relationship between DNA content, tumor histologic type, and age was investigated.
Journal ArticleDOI

Flow cytometric analysis of DNA content as a prognostic indicator in squamous cell carcinoma of the tongue.

TL;DR: It appears that flow cytometry may be an objective prognostic indicator in patients with squamous cell carcinoma of the tongue, and larger series of archival paraffin-embedded flow cytometer analyses are recommended, as well as examination of variables other than the disease-free survival rate.